Hepatitis A Virus Incidence Rates and Biomarker Dynamics for Plasma Donors, United States.
ALT
HAV
IgG
IgM
RNA
RNAemia
United States
alanine aminotransferase
biomarker dynamics
clinical markers
genotypes
hepatitis
hepatitis A
hepatitis A virus
incidence rates
outbreak
plasma donors
virus doubling time
viruses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
entrez:
21
10
2021
pubmed:
22
10
2021
medline:
3
11
2021
Statut:
ppublish
Résumé
The United States is currently affected by widespread hepatitis A virus (HAV) outbreaks. We investigated HAV incidence rates among source plasma donors in the United States since 2016. Serial donations from HAV-positive frequent donors were analyzed for common biologic markers to obtain a detailed picture of the course of infection. We found a considerable increase in incidence rates with shifting outbreak hotspots over time. Although individual biomarker profiles were highly variable, HAV RNA typically had a high peak and a biphasic decrease and often remained detectable for several months. One donor had a biomarker pattern indicative of previous exposure. Our findings show that current HAV outbreaks have been spilling over into the plasma donor population. The detailed results presented improve our comprehension of HAV infection and related public health aspects. In addition, the capture of full RNA curves enables estimation of HAV doubling time.
Identifiants
pubmed: 34670659
doi: 10.3201/eid2711.204642
pmc: PMC8544996
doi:
Substances chimiques
Biomarkers
0
Hepatitis A Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2718-2824Références
Euro Surveill. 2018 Jun;23(23):
pubmed: 29897040
Semin Liver Dis. 2010 Nov;30(4):319-32
pubmed: 20960373
J Virol. 1987 Oct;61(10):3035-9
pubmed: 3041024
Hepatology. 2006 Feb;43(2 Suppl 1):S164-72
pubmed: 16447259
Int J Infect Dis. 2013 Nov;17(11):e939-44
pubmed: 23791857
Nature. 2013 Apr 18;496(7445):367-71
pubmed: 23542590
Transfusion. 2004 Nov;44(11):1555-61
pubmed: 15504159
Food Environ Virol. 2019 Jun;11(2):149-156
pubmed: 30868371
Euro Surveill. 2018 May;23(21):
pubmed: 29845926
J Infect Dis. 2000 Jul;182(1):12-7
pubmed: 10882576
MMWR Morb Mortal Wkly Rep. 2018 Nov 02;67(43):1208-1210
pubmed: 30383739
Transfusion. 2002 May;42(5):537-48
pubmed: 12084161
J Infect Dis. 1995 Mar;171 Suppl 1:S15-8
pubmed: 7876641
Clin Infect Dis. 2020 Dec 17;71(10):e571-e579
pubmed: 32193542
Vox Sang. 2005 Feb;88(2):77-86
pubmed: 15720604
Am Fam Physician. 1999 Apr 15;59(8):2223-30
pubmed: 10221307
Nat Microbiol. 2020 Sep;5(9):1096-1106
pubmed: 32541946
J Med Virol. 1995 Nov;47(3):260-8
pubmed: 8551278
J Med Virol. 2002 Aug;67(4):469-71
pubmed: 12115990
MMWR Morb Mortal Wkly Rep. 2019 May 10;68(18):413-415
pubmed: 31071072
J Virol. 2010 Jun;84(12):6096-102
pubmed: 20357090
Vaccine. 2009 Jan 7;27(2):197-204
pubmed: 18996424